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2ABSTRACT
Aldosterone elicits transcriptional responses in target tissues and also rapidly stimulates the activation of 
protein kinase signalling cascades independently of de novo protein synthesis. Here we investigated 
aldosterone-induced cell growth and extra-cellular regulated kinase 1 and 2 (ERK1/2) mitogen activated 
protein (MAP) kinase signalling in the M1 cortical collecting duct cell line (M1-CCD). Aldosterone 
promoted the growth of M1-CCD cells, an effect that was protein kinase D1 (PKD1), PKC and ERK1/2-
dependent. Aldosterone induced the rapid activation of ERK1/2 with peaks of activation at 2 and 10 to 30 
min after hormone treatment followed by sustained activation lasting beyond 120 min. M1-CCD cells 
suppressed in PKD1 expression exhibited only the early, transient peaks in ERK1/2 activation without the 
sustained phase. Aldosterone stimulated the physical association of PKD1 with ERK1/2 within 2 min of 
treatment. The mineralocorticoid receptor (MR) antagonist RU28318 inhibited the early and late phases of 
aldosterone-induced ERK1/2 activation, and also aldosterone-induced cell growth. Aldosterone-induced 
the sub-cellular redistribution of ERK1/2 to the nuclei at 2 min and to cytoplasmic sites, proximal to the 
nuclei after 30 min. This sub-cellular distribution of ERK1/2 was inhibited in cells suppressed in the 
expression of PKD1. 
Key Words: Aldosterone, Kidney, PKD1, MAPK, Cell growth.
31. INTRODUCTION
The mineralocorticoid hormone aldosterone is an important modulator of ion fluxes across high resistance 
epithelia such as that of the colon and the nephron [1]. In the distal nephron, aldosterone action promotes 
the re-absorption of Na+ from the renal ultra-filtrate back into the blood and can also stimulate the excretion 
of excess K+ from the body through the modulation of ion transporter activity. Aldosterone binds to the 
mineralocorticoid receptor (MR) in the cytoplasm of target cells to promote its dissociation from accessory 
proteins and translocation of the receptor into the cell nucleus. In the nucleus MR interacts with the 
promoter sequences of aldosterone responsive genes to stimulate or suppress their expression [2, 3]. Key 
target genes of MR include those encoding the subunits of aldosterone-sensitive transporters including the 
epithelial Na+ channel (ENaC) and Na+/K+ ATPase [4, 5], and also regulators of transporter activity, such as 
the serum and glucocorticoid regulated kinase (SGK)-1 [6]. In addition to its role as a modulator of ion 
transport, aldosterone can also stimulate cell growth in target tissues such as in glomerular mesangial cells 
[7, 8], vascular smooth muscle cells [9] and cardiac fibroblasts [10] with pathological consequences. 
Aldosterone rapidly activates signalling cascades which promote cell proliferation but the proliferative 
effects of aldosterone on the renal epithelium is poorly characterised. Non-genomic responses to 
aldosterone have been described in various target tissues (Reviewed in [11, 12]). These responses are 
underpinned by the rapid activation of protein kinase signalling cascades. The physiological role of 
aldosterone-induced signalling is not fully understood however there is definite evidence of rapid 
aldosterone effects on K+ channels [13] and Na+/H+ exchanger (NHE) activity in renal cells [14, 15]. The 
transient stimulation of NHE1 activity by aldosterone in cells of the distal nephron is coupled to the rapid 
activation of the extra-cellular regulated kinase (ERK) 1/2 cascade [16].
ERK1/2 activation is associated with the stimulation of cell growth in response to treatment with growth 
factors, hormones and other agonists in diverse tissues. Sustained rather than transient activation of the 
ERK1/2 cascade is required for the stimulation of cell cycle progression by such agonists [17]. This reflects 
the need for advancement through regulatory checkpoints in the cell cycle and the initiation of 
transcriptional events. The promotion of cell proliferation by aldosterone has been linked to the rapid 
activation of the ERK1/2 cascade in mesangial cells [7]. The modulation of ERK1/2 activity has also been 
4implicated in the regulation of Na+ re-absorption by cells of the renal cortical collecting duct (CCD) by 
affecting Na+/K+ ATPase activity [18]. The stimulation of cell growth in response to G-protein coupled 
receptor (GPCR) agonists is dependent on the simultaneous activation of ERK1/2 and protein kinase D1 
(PKD1) [17]. The PKD family of serine threonine protein kinases have been implicated in crucial cellular 
processes including sub-cellular trafficking and cell proliferation (Reviewed in [19]). The activation of PKD 
by aldosterone may contribute to the proliferative effects of the hormone in renal tissues. Aldosterone 
promotes the hypertrophy of cardiac myocytes through a PKD1-dependent mechanism that requires 
sustained activation of PKD1 to modulate gene expression [20]. The activation of ERK1/2 signalling by 
aldosterone in cells derived from the distal nephron has been described by several groups including our 
own [21, 22] and this response has been linked to trans-activation of the epidermal growth factor receptor 
(EGFR) [23]. The aberrant stimulation of proliferation in the distal nephron is one factor in the development 
of polycystic kidney disease [24]. Individuals may carry a genetic predisposition to developing autosomal 
recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) 
through mutations in the genes encoding the fibrocystin or polycystin 1 and 2 genes respectively [25, 26]. 
Chronic hypertension is an exasperating factor in disease progression [27] and controlling hypertension 
through the administration of MR antagonists is a potential means for ameliorating the condition [28]. 
Attenuating the effects of aldosterone on renal epithelial cell proliferation may also have positive 
consequences by slowing cyst growth and so mitigating the disruption of renal function associated with cyst 
enlargement.
The M1-CCD cell line is a widely used model for Na+ transport in the distal nephron. The cells used for 
growth assays in this investigation were sub-confluent in order to maximise any growth stimulatory effect 
of aldosterone without complications of contact inhibition. The aim of future work will be to investigate the 
effects of aldosterone in epithelial monolayers and monolayers of cells with polycystin gene mutations to 
determine a role for aldosterone in the proliferation observed in polycystic kidney disease.  M1-CCD cells 
polarize and form tight junctions when grown on glass or solid plastic surfaces [29]. Cells grown under 
these conditions will form a sufficiently polarized and robust epithelium to transport Na+ directionally with 
the formation of epithelial domes or blisters. We have observed that the Na+/K+-ATPase becomes 
5localized to the basolateral membrane of the M1-CCD cells when grown on glass [30] and that ENaC 
becomes localized to the apical membrane (manuscript in preparation). Studies have also been 
conducted to compare signalling responses on cells grown on non-porous plastic with those grown on 
semi-permeable supports and it was found that for example the aldosterone-induced activation of c-Src 
tyrosine kinase was equivalent in M1-CCD cells grown on these two surfaces [31]. 
We have demonstrated that aldosterone stimulated the activation of PKD in a cortical collecting duct (CCD) 
cell line through the trans-activation of EGFR [32]. In this study we investigate a novel role for PKD1 in MR-
dependent, aldosterone-induced cell growth in CCD cells through the modulation of ERK1/2 activity.  
2. MATERIALS AND METHODS
2.1 Cell Culture
The M1 cell line [33] is derived from the CCD micro-dissected from a mouse transgenic for the early region 
of SV40 virus (strain SV40Ebri7). Cells were grown in 75 cm2 polystyrene culture flasks containing a 1:1 
Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium without phenol red supplemented with 
dexamethasone (5 M), L-glutamine (2 mM), penicillin (100 U.ml-1), streptomycin (100 g.ml-1) and foetal 
bovine serum (10%). The M1-CCD derived cell line stably suppressed in the expression of PKD1 was 
described previously [30]. M1-CCD PKD1 suppressed cell line culture medium also contained the 
aminoglycoside antibiotic G418 (200 g.ml-1), which is toxic for eukaryotic cells not harbouring a plasmid 
containing the neomycin resistance gene and is used for selection and maintenance of stably transfected 
cell lines. Cells were grown in an atmosphere of 70% humidity, 5% CO2 at 37
oC.  
2.2 Preparation of Cell Lysates
For Western blot and immunoprecipitation assays, wild type M1-CCD and PKD knockdown M1-CCD cells 
were plated in 10 cm dishes, grown to 80% confluency and a quiescent state was induced through growth in 
serum and dexamethasone deficient medium for 24 h. Cells were incubated with aldosterone (10 nM) or 
vehicle control for periods indicated. The vehicle control was ethanol diluted 1:10
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in serum free DMEM-F12 
medium. Following treatment confluent monolayers in 10 cm dishes were washed three times with ice cold 
6phosphate buffered saline (PBS) and collected in 1 ml PBS in 1.5 ml centrifuge tubes. Lysates were 
centrifuged for 10 min at 4000 rpm and supernatant removed. The cell pellet was lysed with the addition of 
100 l of lysis buffer (20 mM Tris-HCl pH 7.6, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 1 mM DTT, 10 
µg.ml-1 aprotinin, 10 µg.ml-1 leupeptin, 10 mM NaF, 1 mM PMSF and 0.5% NP40) at the time points 
indicated.  The protein concentration of the lysates was determined and standardized by Bradford Assay 
(Bio-Rad).
2.3 SDS-PAGE and Western Blotting
Cell lysates were cleared by centrifugation then dissolved in Laemmli sample buffer. Proteins were 
separated by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% 
polyacrylamide gels unless otherwise indicated. The proteins were transferred to PVDF membranes and 
probed with the specified primary antibodies diluted in 5% bovine serum albumin (BSA) in Tris buffered 
saline (50 mM Tris-HCl pH 7.5, 150 mM NaCl) according to the supplier’s instructions. Bound antibodies 
were detected using anti-mouse or anti-rabbit horseradish peroxidase secondary antibody conjugates. 
Labelled bands were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences).  Exposed 
films were digitally photographed and subjected to densitometric analysis using GeneSnap software 
(Synoptics).
2.4 Immuno-precipitations
The formation of stable complexes between PKD1 and the ERK1/2 isoforms was determined by co-
immunoprecipitation. Cleared lysates were prepared as above in lysis buffer without DTT and incubated 
with the PKD1 primary antibody. Immuno-complexes were recovered by incubation with protein G 
sepharose (Amersham Biosciences) and isolated by centrifugation. The immuno-complexes were washed 
six times with lysis buffer without DTT then subjected to SDS-PAGE and Western blotting as described.
2.5 Cell Growth Assays
The effect of aldosterone and antagonist treatment on cell growth, were measured using a CellTiter 96 MTT 
(3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide) Cell Proliferation Assay (Promega). Sterile 96-
7well cell culture plates were equilibrated in a humidified, 5% CO2 atmosphere. Cells were detached by 
trypsinization and counted using a Neubauer chamber. Cells were re-suspended to a final concentration of 
1 x 105 cells.ml-1 in cell culture medium with serum. The cells were dispensed (100 l or 1 x 104 cells) into 
each well of the 96-well plate. The cells were left overnight to adhere and then treated with aldosterone or 
vehicle control for 48 h. Cells were pre-treated with antagonists for the times indicated. Following treatment, 
15 µl of tetrazolium dye solution was added to each well and the plate was incubated for 4 h. Post
incubation, 100 µl of solubilisation solution was added to each well for 1 h. The contents of the well were 
mixed on a shaker in order to achieve a uniform solution. The conversion of the MTT tetrazolium substrate 
to the formazan product by viable cells was determined by measuring the absorbance at 570 nm using a 
Multiscan EX plate reader (Thermo).  
2.6 Apoptosis Assays
The effect of aldosterone on the incidence of apoptosis occurring in M1-CCD wild-type versus PKD1 
suppressed cells was investigated using the Cell Death Detection Assay ELISA plus (Roche Diagnostics 
GmbH, Germany). This assay is based on a quantitative sandwich enzyme immunoassay principle using 
mouse monoclonal antibodies directed against DNA and histones, allowing the specific determination of 
mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. M1-CCD cells and M1-CCD PKD1 
suppressed cells were trypsinized and seeded in 96 well plates at a density of 1 x 104 cells per well and left 
to adhere overnight at 37°C, 5% CO2. The cells were then serum starved for 24 h, before being treated with 
10 nM aldosterone or a vehicle control, for 48 h, in the presence of 1 µM dexamethasone and in the 
absence of serum. Following treatment, the cells were lysed and the intact nuclei pelleted by centrifugation. 
An aliquot of supernatant was placed in a strepavidin-coated micro-plate and incubated with a mixture of 
anti-histone-biotin and anti-DNA-peroxidase. After removal of unbound antibodies, the amount of peroxidise 
retained in the immuno-complex was photometrically determined by adding substrate and measuring the 
absorbance at 405 nm. Each treatment was carried out in duplicate and the experiment was repeated twice. 
The enrichment factor was calculated by dividing the background corrected absorbance value at 405 nm for 
aldosterone-treated cells by that for vehicle-treated control cells. 
82.7 Immunofluorescence and Confocal Microscopy
M1-CCD cells were grown in 8-well chamber slides (Nunc) until a confluent monolayer was established. 
Cells were subjected to the treatments indicated then washed in ice-cold PBS and fixed in 4% 
paraformaldehyde in PBS. The cell membranes were disrupted in 0.2% Triton X-100 in TBS. Non specific 
binding of antibodies and fluorescent conjugates were blocked by addition of 3% BSA in PBS. Bound 
antibodies (Total ERK1/2 1:400) were detected using goat anti-rabbit Alexafluor 488 conjugate (1:800) 
(Invitrogen). Cells were mounted in Vectashield (Vector Laboratories) containing 4’, 6-diamidino-2-
phenylindole (DAPI) and examined using a LSM 510 Meta confocal microscope (Zeiss). Excitation 
wave[34]lengths for Alexafluor 488 and DAPI were 488 nm and 364 nm respectively.  Images were 
captured at x 63 magnification and x4 zoom. Scans were performed at 1 m interval depths through the 
fixed cells and single or merged images are presented as XY single planes through the centre of the cells. 
Mean nuclear fluorescence intensity values were obtained using Image J software (Rasband, W.S., Image
J, NIH, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2008). Three random lines were drawn 
through the nucleus of each cell and the mean fluorescence intensity along each line calculated. The mean 
fluorescence intensity for the nucleus of each cell was calculated using these three values. In total ~38 cells 
were quantified for each condition, from four independent experiments. The mean for each condition was 
plotted as a bar chart ± SEM. Statistical significance was examined using a student’s t test. 
2.8 Antibodies and Antagonists
Antibodies were obtained from Cell Signaling Technology (Total ERK1/2, Phospho-Thr202/Tyr204
ERK1/2, Total PKD1, Phospho-PKD1 Ser916); or from Sigma-Aldrich (-actin, anti-mouse IgG 
horseradish peroxidase secondary conjugate and anti-rabbit IgG horseradish peroxidase secondary 
conjugate). The cells were treated with the following pharmacological antagonists at the concentrations 
indicated before addition of the hormone. Spironolactone for the specific inhibition of MR (10 µM), 
Tyrphostin AG1478 for the inhibition of the EGFR (1 µM) and rottlerin (20 µM) for the inhibition of PKC
and PD98059 (1 M) for ERK1/2 cascade inhibition were obtained from Calbiochem. RU28318 (10 µM) 
for the inhibition of MR was obtained from Tocris. Aldosterone was obtained from Steraloids.
92.9 Statistical Analysis
Densitometric values were presented graphically as the means of at least three independent experiments 
+SEM with one representative Western blot. The analysis of variance (ANOVA) of densitometry values 
relative to untreated controls was performed using Dunnett’s modified t-test on one-way ANOVA data, p < 
0.05 was treated as significant (* p < 0.05, ** p < 0.01, *** p < 0.001).
3. RESULTS
3.1 Aldosterone induces growth in M1-CCD cells
Cell signalling cascades rapidly stimulated by aldosterone in the epithelial cells of the distal nephron result 
in the activation of protein kinases that are implicated in cell growth, these include PKC [35] and ERK1/2
[16]. Aldosterone contributes to vascular smooth muscle and cardiac myocyte proliferation but the 
proliferative effects of aldosterone on the renal epithelium is poorly characterised. Aberrant epithelial 
proliferation is an important factor in the development of polycystic kidney disease [24]. Cyst initiation 
occurs more frequently in the aldosterone sensitive distal nephron (ASDN) rather than in the proximal 
nephron where MR is not expressed [36]. The M1-CCD cell line is a widely used model for the ASDN and 
the physiological effects of aldosterone at this site. The effect of aldosterone treatment on M1-CCD cell 
growth was measured using the MTT assay. Measurements were performed on both wild-type M1-CCD 
and M1-CCD cells suppressed in the expression of PKD1 (Fig. 1A). Aldosterone induced a 2 to 3-fold 
increase in cell growth after 48 h treatment relative to untreated or vehicle treated cells. Aldosterone did not 
induce an increase in cell number of M1-CCD cells that were suppressed in PKD1 expression relative to 
vehicle treated cells. This indicates a novel role for PKD1 in promoting aldosterone-induced cell growth in 
epithelial cells of the CCD. The activation of PKD1 by aldosterone is PKC-dependent in M1-CCD cells 
[30]. Pre-treatment with the PKC inhibitor, rottlerin (20 M) for 30 min completely blocked aldosterone 
induced proliferation (Fig. 1B) implicating the activation of PKD1 by PKC in cell growth. ERK1/2 is rapidly 
activated following aldosterone treatment of M1-CCD cells. A role for ERK1/2 in mediating cellular 
proliferation was investigated using the specific ERK1/2 cascade antagonist PD98059. Pre-treatment of 
M1-CCD cells with PD98059 (1 M) for 30 min completely blocked aldosterone-induced cellular proliferation 
(Fig. 1C). The activation of ERK1/2 is thus necessary for aldosterone-induced proliferation in the CCD cells.
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The Cell Death Detection ELISA plus assay was used to confirm that the effect of aldosterone on cell 
growth was due to a stimulation of proliferation rather than the suppression of apoptosis (Fig. 1D). 
Cytoplasmic nucleosome enrichment was quantified as an indicator of the incidence of apoptosis occurring 
in wild-type and PKD1 suppressed cell lines with and without aldosterone treatment. We found no 
statistically significant difference between the amount of apoptosis occurring in M1-CCD wild-type cells and 
M1-CCD PKD1 knockdown cells treated with 10 nM aldosterone for 48 h. These results support the finding 
that the increase in cell number in M1-CCD cells after aldosterone treatment is indeed due to an increase in 
proliferation and that the absence of an increase in cell number in PKD1-deficient cells upon aldosterone 
treatment is due to an impaired induction of cell proliferation rather than an increased rate of apoptosis.
3.2 Aldosterone induces the cyclical activation of ERK1/2
The activation of ERK1/2 MAP kinase is one of the most widely documented rapid signalling responses to 
aldosterone and regulates physiological effects such as cytosolic alkalinisation through NHE activation [16]
and also aldosterone dependent cell proliferation through the modulation of transcriptional responses [8]. 
The activation of ERK1/2 has previously been documented in M1-CCD cells. In the present study M1-CCD 
cells were treated with aldosterone over a time course of 120 min and phosphorylation of ERK1/2 MAP 
kinases at residues Thr202 and Tyr204 was measured (Fig. 2A). The activation of ERK1 and ERK2 is 
differentially regulated in response to certain agonists, however, data presented here suggests that both 
isoforms become equivalently phosphorylated in response to aldosterone, as histograms quantifying ERK1 
phosphorylation kinetics mirrored those of ERK2 phosphorylation. ERK1/2 became transiently 
phosphorylated 2 min after aldosterone treatment and a second peak was observed 10-20 min after 
aldosterone treatment.  A third, sustained phase of ERK1/2 activation was observed that persisted at least 
until 120 min after aldosterone treatment.  Treatment of the cells with an ethanol vehicle control did not elicit 
a response at any point over this time course. Sustained activation of ERK1/2 by GPCR agonists requires 
co-activation of PKD1. The activation of ERK1/2 by aldosterone was investigated in M1-CCD cells 
suppressed in the expression of PKD1 (Fig. 2B).  Aldosterone induced the earlier phases of ERK1/2 
activation after 2 min and 10-20 min treatment in the PKD1 suppressed M1-CCD cells. The later phase of 
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ERK1/2 phosphorylation at 90-120 min after aldosterone treatment was not detected in the PKD1 
suppressed M1-CCD cells. Sustained activation of ERK1/2 by aldosterone in the M1-CCD cells is therefore 
dependent on the expression and concurrent activation of PKD1.
3.3 Activation of PKD1 by aldosterone promotes its physical association with ERK1/2
The PKC-specific antagonist rottlerin, blocks the aldosterone-induced activation of PKD1 in M1-CCD cells 
5 min after treatment with the hormone [30]. Here we show that rottlerin pre-treatment also blocked ERK1/2 
activation 2 min after aldosterone treatment (Fig. 3A). The activation of PKD1 and ERK1/2 are both coupled 
to nPKC activation, however, only the sustained activation of ERK1/2 requires PKD1 co-activation
demonstrating a divergence in the signalling cascade at PKC. We have previously demonstrated that 
aldosterone stimulates the rapid, biphasic activation of PKD1 in the M1-CCD cell line [32]. PKD1 forms 
stable interactions with other protein kinases to facilitate its activation [30] and also forms stable interactions 
with its substrates once activated. Since PKD1 activation is a pre-requisite for sustained ERK1/2 activation, 
the establishment of a stable interaction between these two kinases following aldosterone treatment was 
investigated. Co-immunoprecipitation experiments were performed using a PKD1-specific polyclonal 
antibody. The abundance of ERK1/2 associated with PKD1 was determined before and after aldosterone 
treatment (Fig. 3B). The immunoprecipitated proteins were separated by SDS-PAGE, Western blotted and 
probed with a total ERK1/2 MAP kinase antibody and a total PKD1 specific antibody. ERK1/2 was present 
in complex with PKD1 without aldosterone treatment, however, treatment with the hormone promoted the 
formation of a stable complex between PKD1 and ERK1/2 MAP kinase and the abundance of ERK1/2 
associated with PKD1 increased 8-fold after 2 min hormone treatment as compared to untreated cells. The 
increased physical interaction between PKD1 and ERK1/2 confirmed a role for PKD1 activation in 
modulating aldosterone induced ERK1/2 activity.
3.4 Aldosterone-induced cell growth is dependent on MR and EGFR
The interaction of aldosterone with MR facilitates the role of the receptor as a ligand-dependent 
transcription factor by promoting its nuclear translocation. The role of MR as the initiator of non-genomic 
signalling processes has been the subject of some debate, however the stimulation of at least some of the 
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non-genomic signalling events is MR-dependent. The stimulation of ERK1/2 activation in mesangial cells by 
aldosterone was sensitive to MR antagonism, which also blocked aldosterone induced cell proliferation [7]. 
The involvement of MR in the stimulation of cell growth by aldosterone in the M1-CCD cells was 
investigated using the specific and widely used MR antagonist, spironolactone. Pre-incubation of M1-CCD 
cells with spironolactone (10 M) for 30 min prior to aldosterone treatment blocked the stimulation of 
increased cell growth seen after 48 h treatment with the hormone (Fig. 4A). The activation of PKD1 and 
ERK1/2 by aldosterone in the M1-CCD cells is dependent on the trans-activation of EGFR. EGFR activation 
promotes cell growth and EGF antagonism decreased the growth activity in cysts from a murine polycystic 
kidney disease model [37]. The involvement of EGFR trans-activation in aldosterone-induced M1-CCD cell 
growth was investigated using the EGFR antagonist tyrphostin AG1478. Pre-incubation of the cells with 
AG1478 blocked the stimulation of cell growth by aldosterone over the subsequent 48 h (Fig. 4B). The 
stimulation of cell growth by aldosterone in the M1-CCD cells therefore relies upon the interaction of 
aldosterone with the classical MR and subsequent trans-activation of EGFR.
3.5 Activation of ERK1/2 by aldosterone is mediated by MR 
Different, specific antagonists of MR have produced contradictory data in their attenuation of the non-
genomic, signalling responses stimulated by aldosterone. This includes differing effects in the inhibition of 
the ERK1/2 cascade (reviewed in [11, 12]). These differential effects may be attributed to the differences in 
structural flexibility of open versus closed E-ring structures within the antagonists. The effectiveness of four 
structurally distinct MR antagonists on ERK1/2 activation has been reported in the M1-CCD cell line with 10 
min aldosterone treatment. The authors reported on the inefficacy of the antagonists to blunt the 
aldosterone induced ERK1/2 response at this time-point, however, some inhibition of the ERK1/2 response 
was evident in the presence of canrenoate and RU28318 [22]. Activation of ERK1/2 in our experimental 
system peaked at 2 and 120 min after aldosterone treatment (Fig 2).  The effect of RU28318 on 
aldosterone-induced ERK1/2 activation at these time points was investigated here. The stimulation of 
ERK1/2 activation by aldosterone in M1-CCD cells after 2 and 120 min treatment was blocked by pre-
incubation with the MR antagonist (Fig. 5). The Western blot was re-probed with a total ERK1/2 rabbit 
polyclonal antibody to demonstrate that there was no significant change in ERK1/2 abundance over the 
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course of this experiment. The activation of ERK1/2 during the early transient phase and later sustained 
phase is thus dependent on aldosterone binding to the classical MR.
3.6 Aldosterone induces PKD1-dependent redistribution of ERK1/2
The activation of ERK1/2 in response to mitogens is associated with its translocation from the cytoplasm to 
the nucleus [38], where it participates in the phosphorylation of growth promoting transcription factors such 
as Elk-1 (reviewed in [39]). The stimulation of ERK1/2 phosphorylation in the M1-CCD cells by aldosterone 
was detectable by Western blotting 2 min after hormone treatment (Fig. 2). Changes in the sub-cellular 
localization of ERK1/2 following aldosterone treatment were investigated by confocal immunofluorescence 
microscopy. In untreated wild-type M1-CCD cells, ERK1/2 was uniformly distributed throughout the 
cytoplasm with some nuclear localization (Fig. 6A). Following aldosterone treatment ERK1/2 became 
localized to the nuclei of the cells and quantification of the immunofluorescent staining in the nuclei of single
focal plane scans indicated that there was a two-fold increase in fluorescence in the Alexa 488 emission 
range 2 min after aldosterone treatment. In PKD1 suppressed M1-CCD cells, ERK1/2 was largely localized 
to the cell cytoplasm, again with some ERK1/2 staining evident in the nucleus (Fig. 6B). In these cells, 
aldosterone treatment did not stimulate the redistribution of ERK1/2 to the nuclei as observed in the wild-
type cells even though the transient ERK1/2 phosphorylation at the time point as indicated by Western 
blotting, was comparable in wild-type and PKD1 suppressed cells (Fig. 2). After 30 min aldosterone 
treatment, ERK1/2 localized to the nuclei or to discrete cytoplasmic sites proximal to the nuclei in wild-type 
cells. In PKD1 suppressed cells there was no change in the distribution of ERK1/2, which remained largely 
in the cytoplasm (Fig.7). The translocation of ERK1/2 into the nucleus and subsequently to discrete 
cytoplasmic sites in response to aldosterone is thus dependent on the concurrent activation and association 
with PKD1. 
Aldosterone treatment of wild-type cells resulted in a sustained phase of ERK1/2 phosphorylation that was 
detectable for at least 120 min after treatment. This sustained phase of ERK1/2 activation coincided with 
the accumulation of the kinases at discrete sites in the cytoplasm of wild-type cells, proximal to the nuclei 
with much diminished abundance of the kinases within the nuclei (Fig. 8). Aldosterone treatment of PKD1 
suppressed cells for 120 min did not stimulate a sustained phase of ERK1/2 phosphorylation and ERK1/2 
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remained evenly distributed throughout the cytoplasm similar to that observed after 2 min aldosterone 
treatment. Aldosterone stimulates the sub-cellular redistribution of ERK1/2 to the nuclei within 2 min of 
treatment with a further change in localization to discrete cytoplasmic sites coinciding with its sustained 
activation. Suppression of PKD1 expression attenuated the redistribution of ERK1/2 in response to 
aldosterone over both short and long-term phases of activation. The association of ERK1/2 with the nucleus 
is transient [40] and the export of ERK1/2 back to the cytoplasm is due to dephosphorylation by nuclear 
phosphatases or the nucleus to cytoplasm shuttling of MEK [41].
4. DISCUSSION
The modulation of renal ion transport by aldosterone is well studied and defines a mechanism where the 
action of aldosterone on the kidney can modulate whole body electrolyte balance. The pathophysiological 
consequences of excessive stimulation of aldosterone-dependent processes, particularly Na+ re-absorption 
include hypertension with resulting cardiovascular and renal damage. The promotion of hypertension is 
itself a mechanism by which aldosterone can affect the structure of the renal tubule [42, 43]. Spironolactone 
augments the effects of Angiotensin converting enzyme (ACE) inhibitors in reducing urinary protein 
excretion in chronic kidney failure [43]. ERK1/2 activation has been implicated in aldosterone induced renal 
damage in a hypertensive rat model [44]. The contribution of elevated plasma aldosterone levels to renal 
disease through the direct action of steroid hormones on modulating kidney tubule differentiation and 
proliferation is less well documented. Mesangial cell proliferation is a contributory factor in the development 
of glomerularnephritis and aldosterone promotes proliferation in cells of the mesangial epithelium through a 
mechanism involving the ERK1/2-dependent stimulation of cyclin D1 and cyclin A expression [8]. The 
aldosterone-induced stimulation of cell growth also plays a role in normal renal development. Aldosterone 
has been specifically implicated in the stimulation of cell proliferation and differentiation in the developing 
renal tubule [45]. The in vitro development of renal tubules from isolated embryonic stem cells can only be 
achieved in the presence of aldosterone, an effect that is MR-dependent and not mimicked by 
glucocorticoids or other steroid hormones [45]. 
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Aldosterone-induced ERK1/2 activation in CCD-derived cells is coupled to the activation of NHE1 [21]
resulting in cytoplasmic alkalinization. A transient rise in intracellular pH is variously described as a 
prerequisite or at least permissive for the initiation of cell cycle progression in response to growth factors 
[46, 47] and may be synergistic with the transcriptional events stimulated by ERK1/2 activation to promote 
cell growth. ERK1/2 activation reported in our previous study was biphasic over a 30 min time course with 
peaks 2 min and 20 min after hormone treatment [21]. Aldosterone stimulates activation of ERK1/2 in 
amphibian A6 renal cells with a peak 1 to 2 h after treatment [48]. However, it has been shown that A6 cells 
lack MR and that aldosterone stimulated processes are initiated at the glucocorticoid receptor (GR) [49]. 
The activation of ERK1/2 in the A6 cells was sensitive to GR antagonism and relied on transcriptional up 
regulation of Ki-RasA [48].
Our present study demonstrates that in MR-expressing M1-CCD cells, aldosterone stimulates the sustained 
activation of ERK1/2 up to at least 120 min after hormone treatment through a mechanism that is sensitive 
to MR antagonism (Fig. 9). Aldosterone-induced ERK activation at 2 min was sensitive to the general PKC 
antagonist chelerythrine chloride [21]. We found that only the later phase of ERK1/2 activity was affected by 
PKD1 suppression, suggesting a role for PKC isoforms in the initiation of ERK1/2 activation and a role for 
PKD1 in contributing to the stabilization of ERK1/2 activity.  Further integration of aldosterone-induced 
signalling occurs at the level of EGFR trans-activation. The activation of PKD1 by aldosterone is dependent 
on EGFR trans-activation [32] as is aldosterone-induced ERK1/2 activation [50]. This is indicative of EGFR 
activation having roles in both initiating and sustaining the aldosterone-induced ERK1/2 activity. The 
activation of ERK1/2 in response to estradiol is dependent on PKC activation [51] and ERK activation in 
response to growth factors and cytokines are PKC-dependent [52-54].
PKD1 over-expression potentiates GPCR agonist-induced cell growth and ERK1/2 activation in Swiss-3T3 
fibroblasts [17]. In wild type Swiss 3T3 cells vasopressin stimulated ERK1/2 activation for up to 15 min, 
however heterologous over-expression of PKD1 resulted in increased activation at early time points (5 to 15 
min) that was sustained for at least 240 min. This effect of PKD1 coincided temporally with its activation and 
autophosphorylation.  In this present study we found that aldosterone-induced ERK1/2 activity also 
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coincided with PKD1 activation and in common with the vasopressin work, the earliest phase in 
aldosterone-induced ERK1/2 activation was not PKD1-dependent. Vasopressin did not stimulate 
proliferation of Swiss 3T3 fibroblasts unless PKD1 was over expressed and bombesin-induced proliferation 
of wild-type 3T3 cells was increased by 2 to 3-fold with PKD1 over-expression. We found that aldosterone-
induced CCD cell proliferation was completely blocked with PKD1 suppression confirming the important role 
of this kinase in both GPCR agonist and aldosterone-induced cell growth.
The mechanism by which PKD1 sustains ERK1/2 activity is unclear. PKD1 is a key regulator of sub-cellular 
trafficking events and since ERK1/2 re-distributed to different sites in the cells following aldosterone 
treatment, it is possible that PKD1 not only facilitates rapid nuclear localization of ERK1/2 but also
modulates subsequent redistribution when the two kinases are not physically associated. Additional work is 
required to fully establish the mechanism of sustaining ERK1/2 activation. Since PKD1 also facilitates the 
nuclear localization of MR, the transcriptional responses initiated by aldosterone may also impact on 
ERK1/2 activity so making the PKD1 effect on sustained ERK1/2 activity an indirect linkage. Similar 
coupling of PKD1 activation to sustaining ERK1/2 activity was not observed following EGF treatment of 
Swiss 3T3 fibroblast cells [17]. However the trans-activation of EGFR by aldosterone is required for PKD1 
and ERK1/2 activation by the hormone [23, 32]. In this present study we also show that aldosterone-
induced cell proliferation is sensitive to EGFR antagonism. One explanation is that the activation of EGFR 
by aldosterone occurs via a different mechanism to the dimerization and trans-phosphorylation of EGFR 
stimulated by EGF [32]. Alternatively, EGFR trans-activation is modulated by other, synergistic signalling 
processes when stimulated by aldosterone. The activation of c-Src tyrosine kinase is one of the earliest 
signalling responses to aldosterone in renal cells [31] and the phosphorylation of EGFR by c-Src at Tyr 845 
is essential for aldosterone induced PKD1 activation [32]. The simultaneous activation of c-Src is therefore 
an important modulator of the downstream effects of EGFR trans-activation by aldosterone. The effects of 
PKD1 activation on cell growth are multi-factorial. Not only does PKD1 stabilize ERK activity but also 
increases the duration of RSK and FAK activity in response to GPCR agonists [17, 55]. PKD1 also 
suppresses JNK activity to inhibit apoptosis [56, 57]. PKD1 is therefore a crucial regulator of cell growth. 
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The role of aldosterone-induced cell growth in the repair of physical damage to the renal epithelium 
remains unclear, however, aldosterone is essential for the differentiation and proliferation of renal 
embryonic stem cells in renal tubule formation [45]. The proliferation of the renal epithelium seen in 
ARPKD is mainly localized to the MR-expressing distal nephron [58]. This is circumstantial evidence for a 
role for aldosterone in aberrant proliferation in the distal nephron. Silencing of the ARPKD-associated 
fibrocystin gene in HEK293 cells made them hyper-proliferative to EGF and resulted in over-activation of 
ERK1/2 in response to EGF treatment [59]. Aberrant expression of Heparin binding EGF is detected in 
ARPKD and EGF antagonistic antibodies suppress the mitogenicity of cystic fluid [60].  Hypertension has 
long been associated with the progression of ADPKD [61, 62]. Blockade of the rennin-angiotensin-
aldosterone system (RAAS) to suppress hypertension as a means of slowing cyst formation in ADPKD is 
the subject of current clinical investigation [63].  Antagonism of the aldosterone induced signalling 
pathways that are coupled to EGFR trans-activation leading to cell proliferation may also provide a route 
for pharmacological intervention in treating ADPKD and ARPKD. This study provides new insights into the 
molecular mechanisms, in particular the role of novel protein kinase D, for proliferative effects of 
aldosterone through ‘non-genomic’ signalling cascades in renal CCD.
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FIGURE LEGENDS
Fig. 1. Aldosterone promotes the growth of M1-CCD cells. Aldosterone stimulated cell growth was 
measured using the MTT cell proliferation assay. The assay was performed on wild-type M1-CCD and 
PKD1 suppressed M1-CCD cells (A). Cells were left untreated (0) or treated with aldosterone (Aldo) or 
vehicle control (Con) for 48 h. The MTT assay was performed and absorbance measurements at 570 nm 
were recorded. Values represent the means of four separate experiments ***, p < 0.001 versus wild-type 
M1-CCD cells treated with aldosterone. M1-CCD cells were pre-treated with the PKC antagonist rottlerin 
(20 µM) for 30 min and the appropriate inhibitor vehicle prior to addition of aldosterone or vehicle control 
for 48 h (B). The MTT cell growth assay was performed on M1-CCD WT cells were pre-treated with the 
ERK1/2 antagonist PD98059 (1 µM) for 30 min and the appropriate inhibitor vehicle prior to addition of 
aldosterone or vehicle control for 48h (C). The incidence of apoptosis, as measured by cytoplasmic 
nucleosome enrichment in the M1-CCD wild-type or PKD1 suppressed M1-CCD cells treated with 10 nM 
aldosterone for 48 h was determined (D). The background A405 value was subtracted from the absorbance 
values for each experimental condition. In order to calculate the enrichment factor, the background 
corrected absorbance value for aldosterone-treated cells was divided by that for vehicle-treated cells and 
the results plotted in a bar chart, mean ± SEM. The assay was carried out in duplicate for each condition 
and each experiment repeated twice. 
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Fig. 2. PKD1 modulates aldosterone-induced ERK1/2 activation.  Wild-type M1-CCD cells (A) and 
cells suppressed in PKD1 expression (B) were treated with aldosterone (+) for 2, 5, 10, 20, 30, 60, 90, 
and 120 min or treated with vehicle control (-) for the same time periods. Western blotting was performed 
using a phospho-ERK1/2 Thr202/Tyr204 specific antibody. Membranes were then stripped and re-probed 
with a total ERK1/2. Densitometry was performed on the 44 kDa ERK1 and the 42 kDa ERK2 bands 
separately. Values represent the means of three separate experiments ***, p < 0.001 versus control.
Fig. 3. Aldosterone promotes the association of PKD1 with ERK1/2 MAPK. Wild-type M1-CCD cells 
were treated with aldosterone (+) for 2 min or treated with vehicle control (-) for the same time periods. 
Cells were also pre-treated with the PKC antagonist rottlerin (20µM) for 30 min before aldosterone 
addition. Western blotting was performed using a phospho-ERK1/2 Thr202/Tyr204-specific antibody. 
Membranes were then stripped and re-probed with a total ERK1/2 antibody (A). The interaction between 
PKD1 and ERK1/2 MAP kinase was investigated by co-immunoprecipitation (B). Lysates were prepared 
from M1-CCD cells either treated with 10 nM aldosterone (+) or vehicle control (-) for 2 min or left 
untreated (0). PKD1 was immunoprecipitated from the lysates using a total PKD1 antibody coupled to 
protein G sepharose. Immunoprecipitated proteins were separated by SDS-PAGE. Western blotting was 
performed using a total ERK1/2 antibody or a total PKD1 antibody. 
Fig. 4. Receptor involvement in aldosterone-induced proliferation. M1-CCD cells were pre-treated 
with the MR antagonist spironolactone (10 µM) for 30 min (A) or with the EGFR antagonist Tyrphostin 
AG1478 (1 µM) for 30 min (B) prior to addition of aldosterone (Aldo) or vehicle control (Con) for 48 h. The 
MTT proliferation assay was performed and absorbance values at 570 nm were recorded and subjected 
to statistical analysis. Values represent the means of four separate experiments ***, p < 0.001 versus 
control.
Fig. 5. MR involvement in aldosterone-induced ERK1/2 activation. M1-CCD cells were left untreated 
(0) or treated with aldosterone (10 nM) or vehicle control for 2 min alone or in the presence of the MR 
inhibitor RU28318 (10 M) for 30 min or followed by aldosterone or vehicle control for 2 min or 120 min. 
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Lysates were separated by SDS-PAGE and Western blotted using a phospho-ERK1/2 Thr202/Tyr204-
specific antibody. The membranes were then stripped and re-probed with a total ERK1/2 antibody. Values 
represent the means of three separate experiments ***, p < 0.001 versus aldosterone treated M1-CCD 
cells.
Fig. 6. Aldosterone induces nuclear translocation of ERK1/2. Wild-type M1-CCD (A) and PKD1 
suppressed M1-CCD cells (B) were grown on 8-well chamber slides. Cells were left untreated or treated 
with aldosterone for 2 min.  Cells were fixed and the sub-cellular distribution of ERK1/2 was determined 
by immunofluorescence using an ERK1/2 specific monoclonal antibody and detected using a rabbit anti-
mouse Alexa 488 conjugate (green), nuclei were stained with DAPI (red). Imaging was performed using a 
Zeiss LSM 510 meta confocal microscope at x63 magnification. Representative single XY focal plain 
images through the mid region of the cell monolayer are shown with separate 488 nm and 364 nm 
channels and a merged image of both channels. Bar charts depict the mean nuclear fluorescence 
intensity after ERK1/2 immunocytochemistry in M1-CCD and PKD1 suppressed M1-CCD cells, before 
and after aldosterone treatment for 2 min. Statistical analysis was performed using a student’s t test, *** p 
<0.0001. (WT control n=37, WT Aldo. n=39, PKD1 KD control n=39, PKD1 KD Aldo. n=40). AU: arbitrary 
units.
Fig. 7. ERK1/2 localization after aldosterone treatment for 30 min. Wild-type M1-CCD and PKD1 
suppressed M1-CCD cells were grown on 8-well chamber slides. Cells treated with aldosterone for 30 
min, fixed and the sub-cellular distribution of ERK1/2 was determined by immunofluorescence using an 
ERK1/2 specific monoclonal antibody and detected using a rabbit anti-mouse Alexa 488 conjugate 
(green), nuclei were stained with DAPI (red). Imaging was performed using a Zeiss LSM 510 meta 
confocal microscope at x63 magnification. Representative single XY focal plain images through the mid 
region of the cell monolayer are shown with separate 488 nm and 364 nm channels and a merged image 
of both channels.
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Fig. 8. ERK1/2 localization after aldosterone treatment for 120 min. Wild-type M1-CCD and PKD1 
suppressed M1-CCD cells were grown on 8-well chamber slides. Cells treated with aldosterone for 120 
min, fixed and the sub-cellular distribution of ERK1/2 was determined by immunofluorescence using an 
ERK1/2 specific monoclonal antibody and detected using a rabbit anti-mouse Alexa 488 conjugate 
(green), nuclei were stained with DAPI (red). Imaging was performed using a Zeiss LSM 510 meta 
confocal microscope at x63 magnification. Representative single XY focal plain images through the mid 
region of the cell monolayer are shown with separate 488 nm and 364 nm channels and a merged image 
of both channels.
Fig.9. Aldosterone-induced ERK activation. Aldosterone binds to MR to stabilize the interaction of the 
receptor with specific sequences in target promoters and instigate the assembly of the transcription pre-
initiation complex. The trans-activation of EGFR by aldosterone is dependent on EGFR phosphorylation 
by c-Src  [32] and leads to activation of a nPKC signalling cascade that results in PKD1 activation [30], 
and also to the activation of the ERK1/2 cascade [50].  The phosphorylation of MR by ERK1/2 promotes 
its nuclear localization and transcriptional activity. Concurrent PKD1 activation stabilizes the activation of 
ERK1/2 and facilitates the translocation of ERK1/2 to the nucleus within 2 min of its activation. ERK1/2 
inhabits the nucleus transiently where it phosphorylates transcription factors involved in aldosterone 
induced gene expression.  Changes in the abundance of aldosterone-regulated mRNA species become 
detectable within 20 min of hormone treatment [64, 65]. Within 30 min ERK1/2 starts to be exported from 
the nucleus and becomes localized to discrete sites within the cytoplasm. ERK1/2 accumulation at these 
sites was not observed in cells suppressed in PKD1 expression. After 2 h ERK1/2 is observed at the 
discrete cytoplamic sites or shows a more general cytoplasmic localization, with very low nuclear 
abundance.
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